Tenaya Discusses TN-201 MyPEAK-1 Data, But Focus Remains on TN-401 and Nasdaq Compliance

What happened

Tenaya Therapeutics discussed interim data from its MyPEAK-1 trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy, but the update offered no new quantitative results, reiterating previously reported safety and biomarker signals. This discussion does little to alter the near-term investment thesis, which remains anchored to the TN-401 RIDGE-1 dataset and the July 27, 2026 Nasdaq minimum-bid compliance deadline. The DeepValue report underscores that the stock’s $0.90 price embeds significant risk from a potential reverse split or forced financing if the bid price fails to recover. Meanwhile, TN-201’s progress is a longer-term catalyst with limited bearing on the next 6-9 months. Management’s ability to execute on TN-401 durability and regulatory alignment by year-end 2026 will determine financability and per-share outcomes.

Implication

TN-201’s emerging dataset supports the platform thesis but does not de-risk the binary near-term catalysts. The lack of new granular data keeps the stock in a wait-and-see zone, with downside protection only at the $0.65 attractive entry identified in the DeepValue report.

Thesis delta

The TN-201 discussion provides no incremental data to shift the thesis; the investment case continues to rest on TN-401 performance and listing compliance. The thesis remains unchanged: wait for either Nasdaq bid compliance (≥$1.00 for 10 consecutive days) or a more mature RIDGE-1 dataset demonstrating consistent durability through ~52 weeks.